论文部分内容阅读
一年零11个月的时间对于中国12家制药企业来说足够漫长。7月7日,国家知识产权局电话通知,该局针对美国辉瑞公司治疗阳痿的药品“伟哥”的主要成分枸橼酸西地那非(sildenafilcitrate)的使用所获得的专利无效请求中得到支持,国家知识产权局决定撤销该项专利,“正式通知书会随后发出”。9月27日,辉瑞在北京举行的“‘伟哥’零售药店上市介绍会”上宣布,根据国家药监局和卫生部联合颁发的国食药监市【2004】358号文件,辉瑞的“伟哥”已获准作为唯一的治疗 ED 的药物,在药品零售企业进行销售。
One year and 11 months time long enough for China’s 12 pharmaceutical companies. On July 7, the State Intellectual Property Office, on the telephone, notified that the council has obtained the patent invalidation request obtained from the use of sildenafil citrate, the main ingredient of the drug “Viagra” used in the treatment of impotence by Pfizer in the United States Support, the State Intellectual Property Office decided to withdraw the patent, “formal notice will be issued ”. On September 27, Pfizer announced at its “Introducing Viagra Viagra Pharmacy” in Beijing that according to Pfizer [2004] No. 358 jointly issued by the State Food and Drug Administration and the Ministry of Health, Pfizer’s Viagra has been approved as the only drug that treats ED and is being marketed at pharmaceutical retailers.